10x Genomics, Inc.

10x Genomics Inc Class A's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, 10x Genomics Inc Class A has 130.28M shares outstanding.

As of June 30, 2026, 10x Genomics Inc Class A maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A posted a negative return on equity (ROE) of -9.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.47, reflecting losses generated across the asset base. The company generates approximately 8.91M in revenue per employee across its workforce of 1,210.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.04 indicates how many times 10x Genomics Inc Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A recorded 4.11M in income tax expense. The company reported a pretax loss of -1.31B and -1.31B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 6, 2026, 10x Genomics Inc Class A's stock has gained approximately 539.47% over the past 52 weeks.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A generated 10.78B in revenue and converted that into -1.31B in net income, yielding earnings per share of -10.28. EBITDA reached -706.60M, while operating income came in at -1.60B.

As of June 30, 2026, 10x Genomics Inc Class A holds 9.64B in cash and equivalents against 1.38B in total debt, resulting in a net debt position of -8.78B. Total book value stands at 14.42B, with working capital of 9.72B providing operational flexibility.

10x Genomics Inc Class A produced 2.22B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -98.70M in capital expenditures, free cash flow totaled 2.12B - equivalent to 16.61 per share.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A posted a gross margin of 70.03, reflecting its pricing power and cost economics. The operating margin of -14.88 and net profit margin of -12.18 provide insight into operational efficiency.